AGRX News and Press, Agile Therapeutics Inc. From 02/27/23

Nasdaq has granted to the women's healthcare company Agile Therapeutics ( NASDAQ: AGRX ) a 180-day extension to regain compliance with the stock exchange's listing requirements. The company has until Aug. 14 to meet the requirement. The company was notified of its failure to maint...

PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock...

Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial Officer PR Newswire Appointment of Ernie De Paolantonio to Chief Financial Officer Further Strengthens Leadership Team GRAND RAPIDS, Mich. , Feb. 15, 2023 /PRNewswire/ -- Co...

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team PR Newswire Appointments of Kevin Ostrander to Chief Business Officer and Dr. Niraj Vasisht to Chief Technology Officer Further Strengthen Leadership Team GRAND RAPIDS, Mich. , ...

Twirla and the US FDA have agreed that using electronic health records and insurance claims is appropriate to fulfill post-marketing requirement for Agile Therapeutics ( NASDAQ: AGRX ) Twirla birth control patch. The agency also agreed to extend the study timeline. Interim safety ...

FDA Agrees to Extended Milestones for Long-Term Twirla ® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcar...

(NewsDirect) By Johnny Rice, Benzinga Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga. Agile Therapeutics says it is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. It...

Agile Therapeutics ( NASDAQ: AGRX ) said it expects full year 2023 net revenue to be in the range of $25M to $30M. Birth control patch Twirla factory sales for Q4 2022 are expected to be about 42.2K total cycles, +30% Q/Q. The company said the ~42.6K total cycles would repres...

Fourth Quarter 2022 Twirla Factory Sales Expected to Increase Approximately 30% from Third Quarter 2022 Full Year 2022 Factory Sales Expected to Increase Approximately 232% from Full Year 2021 Full Year 2023 Net Revenue Expected to be in Range of $25-$30 Million PRINCETON,...

(NewsDirect) Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birt...